FDA Deems SEMPREX-D Safe: Cheap Cold Meds on Horizon
Published Date: 9/29/2025
Notice
Summary
The FDA says SEMPREX-D capsules (8 mg acrivastine and 60 mg pseudoephedrine) weren’t pulled from the market because of safety or effectiveness problems. This means generic versions can now get approved if they meet all the rules. People who need allergy and cold relief might see more affordable options soon!
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
ANDA Approvals Allowed for SEMPREX-D
The FDA determined that SEMPREX-D capsules (8 mg acrivastine and 60 mg pseudoephedrine) were not withdrawn from sale for reasons of safety or effectiveness. Because of that determination, the FDA may approve abbreviated new drug applications (ANDAs) for these 8 mg / 60 mg capsules if all other legal and regulatory requirements are met.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in